Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis

Author(s): Aziz Muhammad*, Weissman Simcha, Fatima Rawish, Rajani Sabih, Eid Albert, Nawras Ali

Journal Name: Current Clinical Pharmacology

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Current guidelines recommend the use of vancomycin for the initial treatment of Clostridioides difficile Infection (CDI). Cadazolid, an experimental drug, has been utilized and compared in several studies with varying results.

Methods: A systematic literature search was performed using electronic databases [Medline, Google Scholar and Cochrane] for eligible studies. Randomized Controlled Trials (RCTs) comparing cadazolid with vancomycin for CDI treatment were included. Demographic variables and outcomes (CDI resolution, CDI recurrence, and adverse events) were collected. The primary outcome was clinical cure rate defined as the resolution of CDI at the end of a 10-day course.

Results: Two studies with three RCTs met the inclusion criteria with a total of 1283 patients with CDI who received either cadazolid 250 mg twice daily (624 patients) or vancomycin 125 mg four times daily (659 patients). Clinical cure rate at the end of the treatment was not statistically significant (pooled OR= 0.82; 95% CI = 0.61 to 1.11; p=0.20; I2= 0%). Sustained clinical response at clinical follow-up was also not significantly different (pooled OR = 1.14; 95% CI = 0.91 to 1.43; p=0.27; I2 = 0 %). Cadazolid had a lower recurrence rate than vancomycin (pooled OR = 0.71; 95% CI = 0.52 to 0.98; p=0.04; I2 = 13 %).

Conclusion: Cadazolid is non-inferior to vancomycin and offers a promising alternative for the treatment of CDI. More studies including RCTs and longitudinal studies with large and diverse patient population are needed to further confirm this. Furthermore, cadazolid should also be compared with fidaxomicin in a head-to-head trial to evaluate their efficacy for CDI.

Keywords: Cadazolid, vancomycin, Clostridioides difficile, diarrhea, treatment, recurrence, adverse events.

[1]
Aziz M, Fatima R, Douglass LN, Abughanimeh O, Raza S. Current updates in management of Clostridium difficile infection in cancer patients. Curr Med Res Opin 2019; 35(3): 473-8.
[http://dx.doi.org/10.1080/03007995.2018.1487389] [PMID: 29888965]
[2]
Kali A, Charles MV, Srirangaraj S. Cadazolid: A new hope in the treatment of Clostridium difficile infection. Australas Med J 2015; 8(8): 253-62.
[http://dx.doi.org/10.4066/AMJ.2015.2441] [PMID: 26392822]
[3]
Hodges K, Gill R. Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes 2010; 1(1): 4-21.
[http://dx.doi.org/10.4161/gmic.1.1.11036] [PMID: 21327112]
[4]
Gerding DN, Cornely OA, Grill S, et al. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis 2019; 19(3): 265-74.
[http://dx.doi.org/10.1016/S1473-3099(18)30614-5] [PMID: 30709665]
[5]
Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59(3): 345-54.
[http://dx.doi.org/10.1093/cid/ciu313] [PMID: 24799326]
[6]
Di X, Bai N, Zhang X, et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015; 19(4): 339-49.
[http://dx.doi.org/10.1016/j.bjid.2015.03.006] [PMID: 26001980]
[7]
Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55(Suppl. 2): S93-S103.
[http://dx.doi.org/10.1093/cid/cis499] [PMID: 22752871]
[8]
O’Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136(6): 1913-24.
[http://dx.doi.org/10.1053/j.gastro.2009.02.073] [PMID: 19457419]
[9]
Fatima R, Aziz M. The hypervirulent strain of Clostridium difficile: NAP1/B1/027 - A brief overview. Cureus 2019; 11(1) e3977
[http://dx.doi.org/10.7759/cureus.3977] [PMID: 30967977]
[10]
Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2015; 59(10): 6266-73.
[http://dx.doi.org/10.1128/AAC.00504-15] [PMID: 26248357]
[11]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[12]
Shuster J. Cochrane handbook for systematic reviews for interventions. In: Julian PT. Higgins and Sally Green. 2011; p. 2.
[13]
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928-8.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[14]
Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015; 36(4): 452-60.
[http://dx.doi.org/10.1017/ice.2014.88] [PMID: 25626326]
[15]
Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353(23): 2442-9.
[http://dx.doi.org/10.1056/NEJMoa051639] [PMID: 16322602]
[16]
Murphy S, Xu J, Kochanek K. Deaths: Preliminary data for 2010. National Vital Statistics Reports 60(4)Hyattsville, MD: National Center for Health Statistics. Available from:. https://www.cdc.gov/nchs/data/nvsr/ nvsr60/nvsr60_04.pdf2012
[17]
Peng Z, Jin D, Kim HB, et al. Update on antimicrobial resistance in Clostridium difficile: Resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol 2017; 55(7): 1998-2008.
[http://dx.doi.org/10.1128/JCM.02250-16] [PMID: 28404671]
[18]
Lee C, Louie TJ, Weiss K, et al. Fidaxomicin vs. vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes. Can J Infect Dis Med Microbiol 2016; 2016 8048757
[http://dx.doi.org/10.1155/2016/8048757] [PMID: 27366179]
[19]
Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364(5): 422-31.
[http://dx.doi.org/10.1056/NEJMoa0910812] [PMID: 21288078]
[20]
Baldoni D, Gutierrez M, Timmer W, Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother 2014; 69(3): 706-14.
[http://dx.doi.org/10.1093/jac/dkt401] [PMID: 24106141]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [4 - 10]
Pages: 7
DOI: 10.2174/1574884714666190802124301

Article Metrics

PDF: 16
HTML: 4
EPUB: 1
PRC: 1